Early initiation of continuous renal replacement therapy
DevicePatients will be randomized to either the standard initiation of the CRRT group or the accelerated initiation of the CRRT group with a 1:1 ratio.
NCT Number: NCT06696235
This study was designed to compare the safety and efficacy of early continuous renal replacement therapy with standard continuous renal replacement therapy in the presence of acute kidney injury (stage 2 or greater acute kidney injury according to the KDIGO [The Kidney Disease: Improving Global Outcomes] classification) in patients with advanced cardiogenic shock on extracorporeal membrane oxygenation.
Interested in participating?
Request Info19 year and older
All sexes
Interventional
Phase 4
Samsung Medical Center, Seoul, South Korea
Patients with cardiogenic shock who are placed on extracorporeal membrane oxygenation devices often have increased afterload due to the retrograde arterial flow of the device, resulting in increased left ventricular filling pressures, and optimal full-load management in these patients may be important to improve prognosis. Previous observational studies have reported that the use of renal replacement therapy for full-load management in patients with cardiogenic shock on extracorporeal membrane oxygenation is effective and improves patient survival in cases of severe renal dysfunction when fluid volume reduction is maintained. However, to date, there have been no randomized controlled studies to identify the optimal timing of renal replacement therapy in patients with cardiogenic shock on extracorporeal membrane oxygenation.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
C. Sign of impaired organ perfusion with at least one of the following:
Exclusion criteria
Patients will be randomized to either the standard initiation of the CRRT group or the accelerated initiation of the CRRT group with a 1:1 ratio.
Patients will be randomized to either the standard initiation of the CRRT group or the accelerated initiation of the CRRT group with a 1:1 ratio.
Time frame: 90 days after patient enrollment
Time frame: Up to 30 days
Time frame: Up to 30 days
Time frame: Up to 30 days
Time frame: Up to 30 days
Time frame: Up to 30 days
Time frame: Up to 30 days
Bleeding Academic Research Consortium [BARC] type 3-5
Time frame: Up to 30 days
Cerebral Performance Category
Time frame: Up to 30 days
ICU Stay
Time frame: Up to 30 days
Hospital stay
Time frame: Up to 30 days
Mechanical Ventilation Maintenance
Time frame: Up to 30 days
Renal Replacement Therapy
Time frame: 90 days & 12 months after patient enrollment
Time frame: 90 days & 12 months after patient enrollment
Time frame: 90 days & 12 months after patient enrollment
Left ventricular assisted device implantation or heart transplantation
Time frame: 90 days & 12 months after patient enrollment
Time frame: 90 days & 12 months after patient enrollment
Time frame: 90 days & 12 months after patient enrollment
ischemic or hemorrhagic
Time frame: 90 days & 12 months after patient enrollment
Time frame: 90 days & 12 months after patient enrollment
Time frame: 90 days & 12 months after patient enrollment
Time frame: 90 days & 12 months after patient enrollment
Time frame: Up to 48 hours
Contact information is provided by the study sponsor or research team.
Samsung Medical Center
Other
AcceleRatEd vs. StandarD ContinUous Renal ReplaCement ThErapy for Patients With Cardiogenic Shock Undergoing Veno-arterial ExtraCorporeal Membrane Oxygenator: Randomized-Controlled Trial
Acronym: REDUCE-ECMO
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04082312
Acute Kidney Injury, Cardiogenic Shock
Paris, France
View Trial DetailsNCT05788211
Acute Kidney Injury, Cardiogenic Shock
Pessac, France
View Trial DetailsNCT04917497
Acute Kidney Failure, Acute Kidney Injury
View Trial DetailsNCT02558166
Acute Kidney Injury, Cardiogenic Shock
Amsterdam, North Holland, Netherlands
View Trial Details